{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:37:53Z","timestamp":1793241473605,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg\/kg, range 0.97\u201319.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng\/ml) and similar upper limit (2000 ng\/ml).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-020-03000-0","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T04:02:31Z","timestamp":1601265751000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1925-6228","authenticated-orcid":false,"given":"Stefanie","family":"Fekete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Preissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wewetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mehler-Wex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Romanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"3000_CR1","doi-asserted-by":"crossref","unstructured":"Roessner V, Rothenberger A (2014) Tic disorders. In: Gerlach M, Warnke A, Greenhill L (ed) Psychiatric drugs in children and adolescents. Basic pharmacology and practical applications: tic disorders. Springer, Wien, pp 517\u2013525","DOI":"10.1007\/978-3-7091-1501-5_27"},{"key":"3000_CR2","first-page":"173","volume":"20","author":"Roessner V, Plessen KJ, Rothenberger A, et al ESSTS Guidelines Group","year":"2011","unstructured":"Roessner V, Plessen KJ, Rothenberger A, et al ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 20:173\u2013196","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"3000_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Okun MS, M\u00fcller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J (2019) Practice guideline recommendations summary: treatment of tics in peaple with Tourette syndrome and chonic tic disorders. Neurology 92:896\u2013906","journal-title":"Neurology"},{"key":"3000_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1024\/1422-4917\/a000176","volume":"40","author":"V Roessner","year":"2012","unstructured":"Roessner V, Schoenefeld K, Buse J, Wanderer S, Rothenberger A (2012) Therapie der Tic-St\u00f6rungen. Z Kinder Jugendpsychiatr Psychother 40:217\u2013237","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"3000_CR5","first-page":"25","volume":"111","author":"CJ Bachmann","year":"2014","unstructured":"Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014) Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. Dtsch Arztebl Int 111:25\u201334","journal-title":"Dtsch Arztebl Int"},{"key":"3000_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1024\/1422-4917\/a000430","volume":"44","author":"M Gerlach","year":"2016","unstructured":"Gerlach M, Warnke A (2016) Medikament\u00f6se Behandlung in der Kinder- und Jugendpsychiatrie in Deutschland zwischen ethischen sowie sozial- und haftungsrechtlichen Konflikten. Z Kinder Jugendpsychiatr Psychother 44:249\u2013255","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"3000_CR7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1080\/14740338.2016.1225721","volume":"15","author":"M Gerlach","year":"2016","unstructured":"Gerlach M, Egberts K, Dang S-Y, Plener P, Taurines R, Mehler-Wex C, Romanos M (2016) Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Expert Opin Drug Saf 15:1477\u20131482","journal-title":"Expert Opin Drug Saf"},{"key":"3000_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","volume":"20","author":"M Aravagiri","year":"1999","unstructured":"Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369\u2013377","journal-title":"Biopharm Drug Dispos"},{"issue":"1-02","key":"3000_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gr\u00fcnder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, M\u00f6ssner R, M\u00fcller M, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia M, Stegmann B, Steimer W, Stingl J, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"key":"3000_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/BF02455992","volume":"32","author":"T Norman","year":"1987","unstructured":"Norman T, Chiu E, James RH, Gregory MS (1987) Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease. Eur J Clin Pharmacol 32:583\u2013586","journal-title":"Eur J Clin Pharmacol"},{"key":"3000_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1024\/1422-4917\/a000329","volume":"43","author":"K Egberts","year":"2015","unstructured":"Egberts K, Karwautz A, Plener PL, Mehler-Wex C, K\u00f6lch M, Dang SY, Taurines R, Romanos M, Gerlach M (2015) Pharmakovigilanz in der Kinder- und Jugendpsychiatrie. Z Kinder Jugendpsychiatr Psychother 43:21\u201328","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"3000_CR12","unstructured":"Guy W (1970) Manual for the ECDEU Assessment Battery. U.S. Department of Health, Education, and Welfare, National Institute of Mental Health"},{"key":"3000_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlorfs UG, Beck P et al (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1\u2013100","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"3000_CR14","first-page":"62","volume":"20","author":"E Rey","year":"1982","unstructured":"Rey E, d'Athis P, Richard MO et al (1982) Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms. Int J Clin Pharmacol Ther Toxicol 20:62\u201367","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"3000_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/15622970701361255","volume":"9","author":"KM Kirschbaum","year":"2008","unstructured":"Kirschbaum KM, M\u00fcller MJ, Malevani J, Mobascher A, Burchardt C, Piel M, Hiemke C (2008) Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 9:212\u2013218","journal-title":"World J Biol Psychiatry"},{"issue":"7","key":"3000_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1017\/s0012162200000839","volume":"42","author":"RD Freeman","year":"2000","unstructured":"Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P (2000) An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol 42(7):436\u2013447. https:\/\/doi.org\/10.1017\/s0012162200000839","journal-title":"Dev Med Child Neurol"},{"key":"3000_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1024\/1422-4917.32.4.245","volume":"32","author":"V Roessner","year":"2004","unstructured":"Roessner V, Banaschewski T, Rothenberger A et al (2004) Therapy of tic-disorders. Z Kinder Jugendpsychiatr Psychother 32:245\u2013263","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"3000_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/jnnp.49.9.1055","volume":"49","author":"RA Roos","year":"1986","unstructured":"Roos RA, van der Velde EA, Buruma OJS et al (1986) Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia. J Neurol Neurosurg Psychiatry 49:1055\u20131058","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3000_CR19","first-page":"279","volume":"36","author":"M Strolin-Benedetti","year":"1978","unstructured":"Strolin-Benedetti M, Donath A, Frigerio A et al (1978) Absorption, \u00e9limination et m\u00e9tabolisme du tiapride. Ann Pharm Fr 36:279\u2013288","journal-title":"Ann Pharm Fr"},{"key":"3000_CR20","doi-asserted-by":"crossref","unstructured":"Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS (2003) National Kidney Foundation\u2019s Kidney Disease Outcomes Quality Initiative (2003). National Kidney Foundation\u2019s kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111: 1416\u20131421.","DOI":"10.1542\/peds.111.6.1416"},{"key":"3000_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"C Eggers","year":"1988","unstructured":"Eggers C, Rothenberger A, Berghaus U (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 237:223\u2013229","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"3000_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.yic.0000166405.49473.70","volume":"20","author":"C St\u00f6llberger","year":"2005","unstructured":"St\u00f6llberger C, Huber JO, Finsterer J (2005) Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 20:243\u2013251","journal-title":"Int Clin Psychopharmacol"},{"key":"3000_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","volume":"49","author":"L Farde","year":"1992","unstructured":"Farde L, Nordstr\u00f6m AL, Wiesel FA et al (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Archives of general psychiatry 49:538\u2013544","journal-title":"Relation to extrapyramidal side effects Archives of general psychiatry"},{"key":"3000_CR24","doi-asserted-by":"crossref","unstructured":"Leenders KL, Blauth - Eckmeyer E (1996) PET study with the benzamide tiapride. European Psychiatry 11: 416 s.","DOI":"10.1016\/0924-9338(96)89364-3"},{"key":"3000_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","volume":"28","author":"JF Leckman","year":"1989","unstructured":"Leckman JF, Riddle MA, Hardin MT et al (1989) The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiat 28:566\u2013573","journal-title":"J Am Acad Child Adolesc Psychiat"}],"updated-by":[{"DOI":"10.1007\/s00228-021-03159-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000}}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03000-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03000-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03000-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T01:14:44Z","timestamp":1632791684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03000-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3000"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03000-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00228-021-03159-0","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00228-021-03159-0","URL":"https:\/\/doi.org\/10.1007\/s00228-021-03159-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}